Brown Advisory Inc. Sells 8,265 Shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN)

Brown Advisory Inc. decreased its holdings in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 6.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,200 shares of the company’s stock after selling 8,265 shares during the quarter. Brown Advisory Inc. owned about 0.97% of CollPlant Biotechnologies worth $287,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Wells Fargo & Company MN grew its position in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after purchasing an additional 4,405 shares in the last quarter. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reduced their price target on shares of CollPlant Biotechnologies from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, May 28th.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ:CLGN opened at $1.73 on Wednesday. CollPlant Biotechnologies Ltd. Sponsored ADR has a 52-week low of $1.31 and a 52-week high of $5.45. The firm has a fifty day moving average of $1.79 and a 200 day moving average of $2.71. The firm has a market capitalization of $22.01 million, a PE ratio of -1.42 and a beta of 1.33.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings results on Wednesday, June 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.24. CollPlant Biotechnologies had a negative net margin of 560.92% and a negative return on equity of 87.33%. The business had revenue of $2.06 million during the quarter, compared to analyst estimates of $9.76 million. On average, sell-side analysts forecast that CollPlant Biotechnologies Ltd. Sponsored ADR will post -1.44 EPS for the current fiscal year.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.